Skip to main content

Advertisement

SpringerLink
Log in

Bone health and vitamin D status in alcoholic liver disease

  • Review Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Alcohol consumption is harmful to many organs and tissues, including bones, and it leads to osteoporosis. Hepatic osteodystrophy is abnormal bone metabolism that has been defined in patients with chronic liver disease (CLD), including osteopenia, osteoporosis, and osteomalacia. Decreased bone density in patients with CLD results from decreased bone formation or increased bone resorption. The prevalence of osteopenia in alcoholic liver disease (ALD) patients is between 34 % and 48 %, and the prevalence of osteoporosis is between 11 % and 36 %. Cirrhosis is also a risk factor for osteoporosis. The liver has an important role in vitamin D metabolism. Ninety percent of patients with alcoholic liver cirrhosis have vitamin D inadequacy (<80 nmol/L). The lowest serum vitamin D levels were observed in patients with Child–Pugh class C. Bone densitometry is used for the definitive diagnosis of osteoporosis in ALD. There are no specific controlled clinical studies on the treatment of osteoporosis in patients with ALD. Alcohol cessation and abstinence are principal for the prevention and treatment of osteoporosis in ALD patients, and the progression of osteopenia can be stopped in this way. Calcium and vitamin D supplementation is recommended, and associated nutritional deficiencies should also be corrected. The treatment recommendations of osteoporosis in CLD tend to be extended to ALD. Bisphosphonates have been proven to be effective in increasing bone mineral density (BMD) in chronic cholestatic disease and post-transplant patients, and they can be used in ALD patients. Randomized studies assessing the management of CLD-associated osteoporosis and the development of new drugs for osteoporosis may change the future. Here, we will discuss bone quality, vitamin D status, mechanism of bone effects, and diagnosis and treatment of osteoporosis in ALD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Duggan AE, Duggan JM. Alcoholic liver disease—assessment and management. Aust Fam Physician. 2011;40:590–3.

    PubMed  Google Scholar 

  2. Park BJ, Lee YJ, Lee HR. Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol. 2014;20:2168–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ganry O, Baudoin C, Fardellone P. Effect of alcohol intake on bone mineral density in elderly women: the EPIDOS Study. Epidemiologie de l’Osteoporose. Am J Epidemiol. 2000;151:773–80.

    Article  CAS  PubMed  Google Scholar 

  4. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC: US Government Printing Office; 2010.

    Google Scholar 

  5. National Institute of Alcohol Abuse and Alcoholism. NIAAA council approves definition of binge drinking. NIAAA Newslett. 2004;3:3.

    Google Scholar 

  6. National Osteoporosis Foundation. 2008. Available from: www.nof.org/osteoporosis/diseasefacts.html.

  7. Maurel DB, Boisseau N, Benhamou CL, Jaffre C. Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int. 2012;23:1–16.

  8. Mikosch P. Alcohol and bone. Wien Med Wochenschr. 2014;164:15–24.

    Article  PubMed  Google Scholar 

  9. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 2004;10:648–53.

    Article  PubMed  Google Scholar 

  10. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. 2001;69:321–6.

    Article  CAS  PubMed  Google Scholar 

  11. Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis. 2005;9:747–66.

    Article  PubMed  Google Scholar 

  12. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003;125:941–66.

    Article  PubMed  Google Scholar 

  13. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50 Suppl 1:i1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Diamond T, Stiel D, Lunzer M, Wilkinson M, Posen S. Ethanol reduces bone formation and may cause osteoporosis. Am J Med. 1989;86:282–8.

    Article  CAS  PubMed  Google Scholar 

  15. Giouleme OI, Vyzantiadis TA, Nikolaidis NL, et al. Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology. 2006;53:938–43.

    PubMed  Google Scholar 

  16. Sanchez AJ, Aranda-Michel J. Liver disease and osteoporosis. Nutr Clin Pract. 2006;21:273–8.

    Article  PubMed  Google Scholar 

  17. Nachbandi I, Van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:660–70.

    Article  Google Scholar 

  18. Kimble RB. Alcohol cytokines and estrogens in the control of bone remodelling. Alcohol Clin Exp Res. 1997;21:385–91.

    Article  CAS  PubMed  Google Scholar 

  19. Santolaria F, González-Reimers E, Pérez-Manzano JL, et al. Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol. 2000;22:147–57.

    Article  CAS  PubMed  Google Scholar 

  20. Díez-Ruiz A, García-Saura PL, García-Ruiz P, González-Calvin JL, Gallego-Rojo F, Fuchs D. Bone mineral density, bone turnover markers and cytokines in alcohol-induced cirrhosis. Alcohol Alcohol. 2010;45:427–30.

    Article  PubMed  Google Scholar 

  21. Chakkalakal D. Alcohol-induced bone loss and deficient bone repair. Alcohol Clin Exp Res. 2005;29:2077–90.

    Article  PubMed  Google Scholar 

  22. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46:1271–8.

    Article  CAS  PubMed  Google Scholar 

  23. Crawford AB, Labio ED, Strasser SI, McCaughan GW. Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol. 2006;3:689–99.

    Article  CAS  PubMed  Google Scholar 

  24. Ilich JZ, Brownbill RA, Tamborini L, Crncevic-Orlic Z. To drink or not to drink: how are alcohol, caffeine and past smoking related to bone mineral density in elderly women? J Am Coll Nutr. 2002;21:536–44.

    Article  PubMed  Google Scholar 

  25. Pedrera-Zamorano JD, Lavado-Garcia JM, Roncero-Martin R, Calderon-Garcia JF, Rodriguez-Dominguez T, Canal-Macias ML. Effect of beer drinking on ultrasound bone mass in women. Nutrition. 2009;25:1057–63.

    Article  CAS  PubMed  Google Scholar 

  26. Tucker KL, Jugdaohsingh R, Powell JJ, et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am J Clin Nutr. 2009;89:1188–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Williams FM, Cherkas LF, Spector TD, MacGregor AJ. The effect of moderate alcohol consumption on bone mineral density: a study of female twins. Ann Rheum Dis. 2005;64:309–10.

    Article  CAS  PubMed  Google Scholar 

  28. Venkat KK, Arora MM, Singh P, Derrsai M, Khatkhatay I. Effect of alcohol consumption on bone mineral density and hormonal parameters in physically active male soldiers. Bone. 2009;45:449–54.

    Article  CAS  PubMed  Google Scholar 

  29. Bang CS, Shin IS, Lee SW, et al. Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis. World J Gastroenterol. 2015;21:4038–47.

    Article  PubMed  PubMed Central  Google Scholar 

  30. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80 Suppl:1689S–96S.

  31. Imawari M, Akanuma Y, Itakura H, Muto Y, Kosaka K, Goodman DS. The effects of diseases of the liver on serum 25 hydroxyvitamin D and on serum binding protein for vitamin D and its metabolites. J Lab Clin Med. 1979;93:171–80.

    CAS  PubMed  Google Scholar 

  32. Holick MF. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets. 2011;12:4–18.

    Article  CAS  PubMed  Google Scholar 

  33. Pappa HM, Bern E, Kamin D, Grand R. Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol. 2008;24:176–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. van Driel M, Pols HA, van Leeuwen JP. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des. 2004;10:2535–55.

    Article  PubMed  Google Scholar 

  35. Harada S, Mizoguchi T, Kobayashi Y, et al. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res. 2012;27:461–73.

    Article  CAS  PubMed  Google Scholar 

  36. Anderson PH, Sawyer RK, Moore AJ, May BK, O’Loughlin PD, Morris HA. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res. 2008;23:1789–97.

    Article  CAS  PubMed  Google Scholar 

  37. Baldock PA, Thomas GP, Hodge JM, et al. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res. 2006;21:1618–26.

    Article  CAS  PubMed  Google Scholar 

  38. Artech J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010;55:2624–28.

    Article  Google Scholar 

  39. Savic Z, Damjanov D, Curic N, et al. Vitamin D status, bone metabolism and bone mass in patients with alcoholic liver cirrhosis. Bratisl Lek Listy. 2014;115:573–78.

    CAS  PubMed  Google Scholar 

  40. Malham M, Jorgensen SP, Ott P, et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol. 2011;17:922–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Han YP, Kong M, Zheng S, et al. Vitamin D in liver diseases: from mechanisms to clinical trials. J Gastroenterol Hepatol. 2013;28 Suppl 1:49–55.

    Article  CAS  PubMed  Google Scholar 

  42. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype l)-naïve patients. World J Gastroenterol. 2011;17:5184–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662–87.

    Article  CAS  PubMed  Google Scholar 

  44. Health Quality Ontario. Clinical utility of vitamin d testing: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10:1–93.

    Google Scholar 

  45. Chen EQ, Shi Y, Tang H. New insight of vitamin D in chronic liver diseases. Hepatobiliary Pancreat Dis Int. 2014;13:580–5.

    Article  PubMed  Google Scholar 

  46. Corey RL, Whitaker MD, Crowell MD, et al. Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation. Clin Transplant. 2014;28:579–84.

    Article  CAS  PubMed  Google Scholar 

  47. Tsiaras WG, Weinstock MA. Factors influencing vitamin D status. Acta Derm Venereol. 2011;91:115–24.

    Article  PubMed  Google Scholar 

  48. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet. 2010;19:2739–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Stokes CS, Volmer DA, Grünhage F, Lammert F. Vitamin D in chronic liver disease. Liver Int. 2013;33:338–52.

    Article  CAS  PubMed  Google Scholar 

  51. Turner RT. Skeletal response to alcohol. Alcohol Clin Exp Res. 2000;24:1693–701.

    Article  CAS  PubMed  Google Scholar 

  52. Laitinen K, Välimäki M, Lamberg-Allardt C, et al. Deranged vitamin D metabolism but normal bone mineral density in Finnish noncirrhotic male alcoholics. Alcohol Clin Exp Res. 1990;14:551–6.

    Article  CAS  PubMed  Google Scholar 

  53. Laitinen K, Välimäki M. Alcohol and bone. Calcif Tissue Int. 1991;49 Suppl:S70–3.

  54. Sampson HW. Alcohol, osteoporosis, and bone regulating hormones. Alcohol Clin Exp Res. 1997;21:400–3.

    Article  CAS  PubMed  Google Scholar 

  55. Turner RT, Aloia RC, Segel LD, Hannon KS, Bell NH. Chronic alcohol treatment results in disturbed vitamin D metabolism and skeletal abnormalities in rats. Alcohol Clin Exp Res. 1988;12:159–62.

    Article  CAS  PubMed  Google Scholar 

  56. Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol. 2010;34:618–20.

    Article  CAS  PubMed  Google Scholar 

  57. Guañabens N, Parés A. Osteoporosis in liver cirrhosis. Gastroenterol Hepatol. 2012;35:411–20.

    Article  PubMed  Google Scholar 

  58. Dai J, Lin D, Zhang J, et al. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest. 2000;106:887–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Alvisa-Negrín J, González-Reimers E, Santolaria-Fernández F, et al. Osteopenia in alcoholics: effect of alcohol abstinence. Alcohol Alcohol. 2009;44:468–75.

    Article  PubMed  Google Scholar 

  60. Gonzalez-Reimers E, Alvisa-Negrín J, Santolaria-Fernández F, et al. Vitamin D and nutritional status are related to bone fractures in alcoholics. Alcohol Alcohol. 2011;46:148–55.

    Article  CAS  PubMed  Google Scholar 

  61. Kim MJ, Shim MS, Kim MK, et al. Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis. Korean J Inter Med. 2003;18:174–80.

    Article  CAS  Google Scholar 

  62. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.

  63. Labio ED, Del Rosario DB, Strasser SI, McCaughan GW, Crawford BA. Effect of ascites on bone density measurement in cirrhosis. J Clin Densitom. 2007;10:391–4.

    Article  PubMed  Google Scholar 

  64. López-Larramona G, Lucendo AJ, González-Castillo S, Tenias JM. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. World J Hepatol. 2011;3:300–7.

    Article  PubMed  PubMed Central  Google Scholar 

  65. López-Larramona G, Lucendo AJ, González-Delgado L. Alcoholic liver disease and changes in bone mineral density. Rev Esp Enferm Dig. 2013;105:609–21.

    Article  PubMed  Google Scholar 

  66. Kaemmerer D, Schmidt B, Lehmann G, Wolf G, Settmacher U, Hommann M. Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation. Transplant Res. 2012;1:7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144:239–48.

    Article  CAS  PubMed  Google Scholar 

  68. Guañabens N, Parés A. Management of osteoporosis in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:438–45.

    Article  PubMed  Google Scholar 

  69. González-Reimers E, Durán-Castellón MC, Martín-Olivera R, et al. Effect of zinc supplementation on ethanol-mediated bone alterations. Food Chem Toxicol. 2005;43:1497–505.

    Article  PubMed  Google Scholar 

  70. Iwaniec UT, Trevisiol CH, Maddalozzo GF, Rosen CJ, Turner RT. Effects of low-dose parathyroid hormone on bone mass, turnover, and ectopic osteoinduction in a rat model for chronic alcohol abuse. Bone. 2008;42:695–701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Dresner-Pollak R, Gabet Y, Steimatzky A, et al. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology. 2008;134:259–67.

    Article  CAS  PubMed  Google Scholar 

  72. Parés A, Guañabens N. Treatment of bone disorders in liver disease. J Hepatol. 2006;45:445–53.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Diskapi Teaching and Research Hospital, Ankara, Turkey

    M. Kizilgul, O. Ozcelik & T. Delibasi

Authors
  1. M. Kizilgul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Ozcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Delibasi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Kizilgul.

Ethics declarations

Conflict of interest

MK, OO, and TD declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kizilgul, M., Ozcelik, O. & Delibasi, T. Bone health and vitamin D status in alcoholic liver disease. Indian J Gastroenterol 35, 253–259 (2016). https://doi.org/10.1007/s12664-016-0652-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-016-0652-1

Keywords

Search

Navigation